盟科药业(688373.SH)发布公告，公司股东Genie Pharma对公司2025年第二次临时股东大会所审议多项议 案均投反对票。Genie Pharma合计持有公司股份数量7157.28万股，占公司股份总数的10.92%。征集投 票权的起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参与定增资金存在不 确定性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升盈利能力不确定性 以及研发领域协同效应小等。 ...

智通财经APP讯，盟科药业(688373.SH)发布公告，公司股东Genie Pharma对公司2025年第二次临时股东 大会所审议多项议案均投反对票。Genie Pharma合计持有公司股份数量7157.28万股，占公司股份总数的 10.92%。征集投票权的起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参 与定增资金存在不确定性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升 盈利能力不确定性以及研发领域协同效应小等。 ...

Core Points - Genie's Pharma, the largest shareholder of Amgen Pharmaceutical, holds 71.57 million shares, accounting for 10.92% of the total shares [1] - Genie Pharma opposes several proposals at the upcoming extraordinary general meeting, including a plan for Amgen to issue shares to HaiJing Pharmaceutical to raise up to 1.033 billion yuan [1] - If the share issuance is completed, HaiJing Pharmaceutical will hold 20% of Amgen's shares and nominate 5 out of 9 board members, making it the controlling shareholder [1] Proposal Details - The proposal involves Amgen raising funds through a specific share issuance plan, which has raised concerns from Genie Pharma [1] - Genie Pharma's objections include uncertainties regarding the funding from HaiJing Pharmaceutical, potential loss of independence for Amgen, and doubts about the synergy in research and development [1] - Concerns are also raised about HaiJing Pharmaceutical's compliance history and management capabilities, which could impact Amgen's operations [1]

上海盟科药业股份有限公司 2025 年第二次临时股东大会 会议资料 二 O 二五年十月 上海盟科药业股份有限公司 2025 年第二次临时股东大会会议资料 证券代码：688373 证券简称：盟科药业 | 2025 年第二次临时股东大会会议议程 5 | | | --- | --- | | 议案一 | 8 | | 关于公司符合向特定对象发行股票条件的议案 | 8 | | 议案二 | 9 | | 关于公司向特定对象发行股票方案的议案 | 9 | | 议案三 | 12 | | 关于公司向特定对象发行股票预案的议案 | 12 | | 议案四 | 13 | | 关于公司向特定对象发行股票方案论证分析报告的议案 | 13 | | 议案五 | 14 | | 关于公司向特定对象发行股票募集资金使用可行性分析报告的议案 14 | | | 议案六 | 15 | | 关于公司引入战略投资者并签署《战略合作协议》的议案 | 15 | | 议案七 | 16 | | 关于签署《附条件生效的向特定对象发行股份认购协议》的议案 16 | | | 议案八 | 17 | | 关于公司向特定对象发行股票涉及关联交易事项的议案 | 17 | | 议案九 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-052 上海盟科药业股份有限公司 关于2025年第二次临时股东大会增加临时提案暨补 充通知的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 股东大会有关情况 1. 股东大会的类型和届次： 2025年第二次临时股东大会 | 股份类别 | 股票代码 | 股票简称 | 股权登记日 | | --- | --- | --- | --- | | 股 A | 688373 | 盟科药业 | 2025/9/24 | 二、 增加临时提案的情况说明 公司已于2025 年 9 月 23 日公告了股东大会召开通知，单独或者合计持有 10.92%股份的股东Genie Pharma，在2025 年 9 月 24 日提出临时提案并书面提交 股东大会召集人。股东大会召集人按照《上海证券交易所科创板上市公司自律监 2. 股东大会召开日期：2025 年 10 月 9 日 3. 股东大会股权登记日： 1. 提案人：Genie Pharma 2. 提案程序说明 管指引第 1 号 — 规范运 ...

公司及董事会全体成员保证公告内容与 Genie Pharma 提供的信息一致。 证券代码：688373 证券简称：盟科药业 公告编号：2025-051 上海盟科药业股份有限公司 关于股东 Genie Pharma 公开征集投票权的公告 股东 Genie Pharma 保证向公司提供的信息内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 重要内容提示： 按照《中华人民共和国证券法》《上市公司股东会规则》《公开征集上市公 司股东权利管理暂行规定》《上海盟科药业股份有限公司章程》或其他有关规定， 持有上市公司1%以上有表决权股份的股东Genie Pharma作为征集人，就公司拟于 1 征集投票权的起止时间：2025年9月25日至2025年10月6日 Genie Pharma（以下简称"征集人"）对上海盟科药业股份有限公司（以下简 称"公司"或"上市公司"）2025年第二次临时股东大会所审议议案除议案9 外均投反对票； 截至征集公告披露日，征集人Genie Pharma合计持有公司股份数量71,572,817 股，均为有表决权股份，占公司股份总数的10.92%； 征集人 ...

盟科药业(688373.SH)公告称，股东GeniePharma对公司2025年第二次临时股东大会所审议多项议案均投 反对票。GeniePharma合计持有公司股份数量71,572,817股，占公司股份总数的10.92%。征集投票权的 起止时间为2025年9月25日至2025年10月6日。征集人反对原因包括海鲸药业参与定增资金存在不确定 性、销售渠道和人员混同风险、募投项目进度不及预期、利用海鲸药业产能提升盈利能力不确定性以及 研发领域协同效应小等。 ...

Core Viewpoint - The company Mengke Pharmaceutical plans to issue shares to Haiqing Pharmaceutical, which will result in a change of control, with Haiqing holding 20% of the shares and becoming the controlling shareholder [6] Group 1: Share Issuance Details - Mengke Pharmaceutical intends to issue up to 163,901,373 shares at a price of 6.30 yuan per share, raising a total of no more than 1.033 billion yuan, which will be used for daily R&D and operational investments [2][4] - The issuance is aimed at enhancing the company's commercialization capabilities and expanding product sales, as the company currently has limited sales coverage and only one product on the market [4][8] Group 2: Financial Performance - Mengke Pharmaceutical's revenue for 2022, 2023, and 2024 is projected to be 482.07 million yuan, 907.76 million yuan, and 1.30 billion yuan, respectively, with a net profit of -220 million yuan, -421 million yuan, and -441 million yuan [8] - The company has maintained high R&D expenditures, with amounts of 150 million yuan, 345 million yuan, and 369 million yuan for the same years, representing 321%, 379%, and 284% of revenue [8] Group 3: Opposition to the Share Issuance - A board member opposed the share issuance, questioning the fairness, reasonableness, and synergy of the transaction, as well as the clarity of the fundraising plan [5][7] - The board member highlighted the existence of other potential investors with strong collaboration intentions, suggesting that the company did not conduct sufficient investigation and negotiation [7] Group 4: Haiqing Pharmaceutical Overview - Haiqing Pharmaceutical is a research-driven modern pharmaceutical enterprise, focusing on chemical preparations and active pharmaceutical ingredients, with significant market share in the vitamin D2 prescription drug sector [2] - The company has provided over 200 pharmaceutical research or clinical trial services to more than 100 enterprises, including major domestic pharmaceutical companies [2]

Core Viewpoint - The strategic investment by Haiqing Pharmaceutical in Mengke Pharmaceutical marks a significant shift in the latter's ownership structure, with Haiqing becoming the controlling shareholder and aiming to enhance Mengke's capabilities in the antibiotic drug development sector [1][3][4]. Financing and Ownership Changes - Mengke Pharmaceutical plans to raise 1.033 billion yuan through a private placement of 164 million shares at a price of 6.3 yuan per share, which will be used for daily research and operational expenses [3][4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in Mengke and will nominate five directors to the board, giving it majority control [1][3]. - This marks the first private placement since Mengke's IPO in August 2022, which raised 1.061 billion yuan [3][4]. Financial Performance - From 2021 to mid-2025, Mengke Pharmaceutical generated total revenue of 344 million yuan but incurred a net loss of 1.447 billion yuan, with total R&D expenses amounting to 1.132 billion yuan [6][7]. - The company has not yet achieved profitability, with significant losses reported each year since its product commercialization began in 2021 [6][7]. Strategic Collaboration - A strategic cooperation agreement has been signed between Mengke and Haiqing, focusing on leveraging Mengke's expertise in multi-drug resistant bacteria and Haiqing's established R&D and commercialization capabilities [4][7]. - The collaboration aims to enhance both companies' core competitiveness and facilitate the commercialization of Mengke's products, particularly in the antibiotic sector [4][7]. Market Reaction - Following the announcement of the private placement and strategic partnership, Mengke Pharmaceutical's stock price surged by 20.02%, closing at 9.71 yuan per share [5]. Future Projections - If the collaboration is successful, Mengke aims to achieve sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026, 2027, and 2028, respectively [7].

Core Viewpoint - The company plans to raise up to 1.033 billion yuan through a private placement, which will enhance its financial strength and accelerate clinical research and development efforts [4][6]. Group 1: Company Financing and Ownership Changes - The company intends to issue 164 million shares at a price of 6.3 yuan per share to Nanjing Haiqing Pharmaceutical, raising no more than 1.033 billion yuan, which will be used for daily R&D and operational investments [4]. - Following the issuance, Haiqing Pharmaceutical will hold a 20% stake in the company, becoming the controlling shareholder, with Zhang Xiantao as the actual controller [4]. Group 2: Strategic Partnerships and Market Expansion - Haiqing Pharmaceutical, a key player in the chemical pharmaceutical sector, will leverage its extensive sales network and experience to help the company expand its hospital coverage and accelerate commercialization [5]. - The company has set sales revenue targets of 260 million yuan, 388 million yuan, and 600 million yuan for the years 2026 to 2028, respectively [5]. Group 3: Clinical Development Acceleration - The financing will significantly enhance the company's capital strength, expediting the overseas clinical development of antibacterial drugs MRX-5 and MRX-8, which have already completed Phase I trials [6]. - MRX-5 has received FDA orphan drug designation, and successful Phase II trials could substantially increase the company's value [6]. - Surplus funds will also support the advancement of the company's preclinical pipeline, which includes peptide conjugates, antibody-drug conjugates, and other anti-infective drugs [6].